Apex Medical Corp. (4106.TW)
TWD 21.45
(-0.46%)
TWD 21.45
(-0.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 2.64 Billion TWD | -0.62% |
| 2022 | 2.66 Billion TWD | 12.2% |
| 2021 | 2.37 Billion TWD | 18.46% |
| 2020 | 2 Billion TWD | -1.58% |
| 2019 | 2.03 Billion TWD | -3.3% |
| 2018 | 2.1 Billion TWD | 0.79% |
| 2017 | 2.08 Billion TWD | 4.97% |
| 2016 | 1.99 Billion TWD | -1.27% |
| 2015 | 2.01 Billion TWD | -10.93% |
| 2014 | 2.26 Billion TWD | 12.22% |
| 2013 | 2.01 Billion TWD | 9.28% |
| 2012 | 1.84 Billion TWD | 5.56% |
| 2011 | 1.74 Billion TWD | 5.26% |
| 2010 | 1.66 Billion TWD | 5.32% |
| 2009 | 1.57 Billion TWD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q1 | 646.68 Million TWD | -4.74% |
| 2024 Q2 | 584.36 Million TWD | -9.64% |
| 2023 Q3 | 564.86 Million TWD | -19.72% |
| 2023 Q4 | 678.87 Million TWD | 20.18% |
| 2023 FY | 2.64 Billion TWD | -0.62% |
| 2023 Q1 | 699.76 Million TWD | 0.45% |
| 2023 Q2 | 703.61 Million TWD | 0.55% |
| 2022 Q2 | 680.13 Million TWD | 14.23% |
| 2022 Q4 | 696.63 Million TWD | 0.73% |
| 2022 FY | 2.66 Billion TWD | 12.2% |
| 2022 Q3 | 691.56 Million TWD | 1.68% |
| 2022 Q1 | 595.39 Million TWD | -3.71% |
| 2021 Q3 | 598.41 Million TWD | 3.81% |
| 2021 Q4 | 618.33 Million TWD | 3.33% |
| 2021 Q1 | 580.86 Million TWD | 4.89% |
| 2021 Q2 | 576.44 Million TWD | -0.76% |
| 2021 FY | 2.37 Billion TWD | 18.46% |
| 2020 Q2 | 508.28 Million TWD | 21.87% |
| 2020 Q1 | 417.06 Million TWD | -19.23% |
| 2020 FY | 2 Billion TWD | -1.58% |
| 2020 Q4 | 553.79 Million TWD | 5.51% |
| 2020 Q3 | 524.88 Million TWD | 3.26% |
| 2019 Q3 | 482.21 Million TWD | -7.65% |
| 2019 FY | 2.03 Billion TWD | -3.3% |
| 2019 Q1 | 515.46 Million TWD | -9.33% |
| 2019 Q2 | 522.17 Million TWD | 1.3% |
| 2019 Q4 | 516.38 Million TWD | 7.09% |
| 2018 Q1 | 499.24 Million TWD | -2.46% |
| 2018 FY | 2.1 Billion TWD | 0.79% |
| 2018 Q4 | 568.49 Million TWD | 15.19% |
| 2018 Q3 | 493.52 Million TWD | -9.36% |
| 2018 Q2 | 544.48 Million TWD | 9.06% |
| 2017 Q4 | 511.81 Million TWD | -9.63% |
| 2017 Q1 | 469.03 Million TWD | -10.79% |
| 2017 Q3 | 566.34 Million TWD | 4.47% |
| 2017 Q2 | 542.08 Million TWD | 15.57% |
| 2017 FY | 2.08 Billion TWD | 4.97% |
| 2016 FY | 1.99 Billion TWD | -1.27% |
| 2016 Q1 | 508.57 Million TWD | -4.02% |
| 2016 Q2 | 526.24 Million TWD | 3.47% |
| 2016 Q3 | 429.7 Million TWD | -18.35% |
| 2016 Q4 | 525.75 Million TWD | 22.35% |
| 2015 Q4 | 529.88 Million TWD | 26.73% |
| 2015 Q3 | 418.1 Million TWD | -24.11% |
| 2015 Q2 | 550.93 Million TWD | 6.57% |
| 2015 Q1 | 516.96 Million TWD | -4.75% |
| 2015 FY | 2.01 Billion TWD | -10.93% |
| 2014 Q4 | 542.72 Million TWD | -2.18% |
| 2014 Q3 | 554.83 Million TWD | -5.09% |
| 2014 Q1 | 581.19 Million TWD | 11.55% |
| 2014 FY | 2.26 Billion TWD | 12.22% |
| 2014 Q2 | 584.6 Million TWD | 0.59% |
| 2013 Q4 | 521 Million TWD | 5.4% |
| 2013 FY | 2.01 Billion TWD | 9.28% |
| 2013 Q3 | 494.33 Million TWD | -3.13% |
| 2013 Q2 | 510.29 Million TWD | 3.86% |
| 2013 Q1 | 491.34 Million TWD | 8.47% |
| 2012 Q1 | 442.31 Million TWD | -4.43% |
| 2012 FY | 1.84 Billion TWD | 5.56% |
| 2012 Q3 | 420.61 Million TWD | -10.53% |
| 2012 Q2 | 470.09 Million TWD | 6.28% |
| 2012 Q4 | 452.97 Million TWD | 7.69% |
| 2011 Q1 | 445.21 Million TWD | 18.42% |
| 2011 FY | 1.74 Billion TWD | 5.26% |
| 2011 Q2 | 430.07 Million TWD | -3.4% |
| 2011 Q3 | 410.42 Million TWD | -4.57% |
| 2011 Q4 | 462.8 Million TWD | 12.76% |
| 2010 Q3 | 386.77 Million TWD | -20.2% |
| 2010 FY | 1.66 Billion TWD | 5.32% |
| 2010 Q4 | 375.97 Million TWD | -2.79% |
| 2010 Q1 | 413.82 Million TWD | 0.0% |
| 2010 Q2 | 484.64 Million TWD | 17.12% |
| 2009 FY | 1.57 Billion TWD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Excelsior Medical Co., Ltd. | 8.23 Billion TWD | 67.872% |
| OK Biotech Co., Ltd. | 1.19 Billion TWD | -122.077% |
| Applied BioCode Corporation | 395.16 Million TWD | -569.871% |